Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma

Trial Profile

Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Vitespen (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 22 Jan 2016 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 22 Jan 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018 as per ClinicalTrials.gov record.
    • 22 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top